Syntis Bio Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$5M
- Investors
-
12
Syntis Bio General Information
Description
Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. The company's drug uses formulations for oral therapies that target specific tissues to leverage the small intestine's biology for metabolic and rare disease treatments through a daily nutrient-blocking pill using transient polymer coatings and gut-stable enzyme therapies, enabling researchers to treat patients within a broader disease category and with effective options that mimic surgical benefits and reduce dietary restrictions.
Contact Information
Website
www.syntis.bioCorporate Office
- 135 Morrissey Boulevard
- Suite 101A
- Boston, MA 02125
- United States
Corporate Office
- 135 Morrissey Boulevard
- Suite 101A
- Boston, MA 02125
- United States
Syntis Bio Timeline
Syntis Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 01-Jul-2025 | $5M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series A) | 24-Jun-2025 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC | 17-Aug-2022 | $15.4M | $15.4M | Completed | Clinical Trials - Phase 1 |
Syntis Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed | 5,854,507 | $0.000100 | 6% | $2.63 | $2.63 | 1x | $2.63 | 20.42% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Syntis Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Syntis Bio Patents
Syntis Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260315396-A1 | Dosage forms for gastrointestinal synthetic epithelial linings | Pending | 09-Apr-2025 | ||
| WO-2026217699-A1 | Dosage forms for gastrointestinal synthetic epithelial linings | Pending | 09-Apr-2025 | ||
| AU-2024354209-A1 | Synergistic permeation enhancers for gastrointestinal synthetic epithelial linings | Pending | 28-Sep-2023 | ||
| EP-4784166-A1 | Synergistic permeation enhancers for gastrointestinal synthetic epithelial linings | Pending | 28-Sep-2023 | ||
| WO-2025072841-A1 | Synergistic permeation enhancers for gastrointestinal synthetic epithelial linings | Inactive | 28-Sep-2023 | A61K9/0053 |
Syntis Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Syntis Bio Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| Apollo Research Labs | Corporation | Minority | ||
| Cerberus Ventures | Venture Capital | Minority | ||
| Mansueto Investments | Corporation | Minority | ||
| Sky9 Capital | Venture Capital | Minority |
Syntis Bio FAQs
-
When was Syntis Bio founded?
Syntis Bio was founded in 2022.
-
Where is Syntis Bio headquartered?
Syntis Bio is headquartered in Boston, MA.
-
What is the size of Syntis Bio?
Syntis Bio has 29 total employees.
-
What industry is Syntis Bio in?
Syntis Bio’s primary industry is Drug Discovery.
-
Is Syntis Bio a private or public company?
Syntis Bio is a Private company.
-
What is Syntis Bio’s current revenue?
The current revenue for Syntis Bio is .
-
How much funding has Syntis Bio raised over time?
Syntis Bio has raised $48.4M.
-
Who are Syntis Bio’s investors?
National Institutes of Health, Apollo Research Labs, Cerberus Ventures, Mansueto Investments, and Sky9 Capital are 5 of 12 investors who have invested in Syntis Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
